| scholarly article | Q13442814 |
| P2093 | author name string | Kiyosuke Ishiguro | |
| Naotaka Uchida | |||
| Takako Suda | |||
| P2860 | cites work | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 |
| Molecular portraits of human breast tumours | Q28032461 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Breast cancer classification and prognosis based on gene expression profiles from a population-based study | Q35918291 | ||
| Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 | ||
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. | Q37155629 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study | Q42492770 | ||
| Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. | Q43234010 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| P433 | issue | 2 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 51-56 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Yonago Acta Medica | Q15765174 |
| P1476 | title | Effect of chemotherapy for luminal a breast cancer | |
| P478 | volume | 56 |
| Q51827185 | Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer. |
| Q42113818 | Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes |
| Q36228444 | Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study |
| Q39032812 | Harnessing benefit from targeting tumor associated carbohydrate antigens |
| Q40037487 | Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling. |
| Q33859521 | Pilot Survey of Breast Cancer Management in Sub-Saharan Africa |
Search more.